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Abstract 37 
 38 
Background-Mast cells (MCs) crucially contribute to many inflammatory 39 
diseases. However, the physiological controls preventing excessive MCs 40 
activities in human skin are incompletely understood.  41 
 42 
Objective-Since endocannabinoids are important neuroendocrine MCs 43 
modifiers, we investigated how cannabinoid receptor (CB) 1-44 
stimulation/inhibition affects human skin MCs biology in situ. 45 
 46 
Methods-This was investigated in the MCs-rich connective tissue sheath (CTS) 47 
of organ-cultured human scalp hair follicles (HFs) by quantitative 48 
(immuno)histomorphometry, ultstrastructural and qPCR techniques, using CB1 49 
agonists or antagonist, CB1 knock-down, or CB1 knockout mice. 50 
 51 
Results-Kit+ MCs within the CTS of human HFs express functional CB1 52 
receptors, whose pharmacological blockade or gene silencing significantly 53 
stimulated both, MCs degranulation and maturation from resident progenitor 54 
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cells in situ (i.e. enhanced the number of tryptase+, FcRI or chymase+ CTS-55 
MCs). This was, at least in part, stem cell factor-dependent. CB1 agonists 56 
counteracted the MCs-activating effects of classical MCs secretagogues. 57 
Similar phenomena were observed in CB1 knock-out mice, attesting to the in 58 
vivo relevance of this novel MCs-inhibitory mechanism. 59 
 60 
Conclusion-Using human HF organ-culture as an unconventional, but clinically 61 
relevant model system for studying MCs biology in situ, we show that normal 62 
skin MCs are tightly controlled by the endocannabinoid system. This limits 63 
excessive MCs activation and maturation from resident progenitors via “tonic” 64 
CB1 stimulation by locally synthesized endocannabinoids. The excessive MCs 65 
numbers and activation in allergic and other chronic inflammatory skin diseases 66 
may partially arise from resident intracutaneous MC progenitors, e.g. due to 67 
insufficient CB1-stimulation. Therefore, CB1-stimulation is a promising strategy 68 
for the future management of allergy and MCs-dependent skin diseases. 69 
 70 
 71 
Capsule Summary 72 
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CB1-stimulation by endocannabinoids is required to limit human and murine 73 
skin mast cells activation as well as mast cell maturation from resident 74 
progenitors in situ. Therefore, mast cell-dependent human skin diseases should 75 
profit from CB1 stimulation. 76 
 77 
Key Messages 78 
# Endocannabinoids control not only human skin mast cell activation but also 79 
their maturation from resident progenitor cells in situ via CB1 stimulation. 80 
# Endocannabinoids also regulate stem cell factor (SCF) expression in human 81 
hair follicle epithelium (increased SCF production via CB1 stimulation). 82 
# CB1-stimulation is a promising strategy in the future management of allergy 83 
and other mast cell-dependent inflammatory diseases by limiting skin mast cell 84 
activation and maturation. 85 
 86 
 87 
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Abbreviations used 93 
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ORS   outer root sheath 97 
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SCF   stem cell factor 100 
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INTRODUCTION 102 
 103 
In many developed countries, the incidence of allergic diseases is increasing to 104 
epidemic proportions, affecting up to 30% of the populationS26. Thus, these 105 
diseases constitute a considerable burden to affected patients and to healthcare 106 
providers. Given the crucial role that mast cells (MCs) play in the pathogenesis 107 
and clinical phenotype of allergic diseases and many other chronic inflammatory 108 
disorders1, 2, we clearly need a better understanding of how healthy human 109 
tissues that are very rich in MCs (such as skin or bronchial mucosa) avoid 110 
excessive MCs activities and numbers under physiological circumstances3. This 111 
should open new, more effective, and better-tolerated avenues to counteracting 112 
the critical input of MCs into allergic and many other chronic inflammatory 113 
diseases. 114 
As key protagonists of innate immunity, MCs not only play a pivotal role in anti-115 
infection defence and “danger”-response systems, but also regulate 116 
inflammation, tissue repair, and tissue remodelling1-5. Though it is now 117 
understood that MCs are involved in both inciting and limiting inflammation2, 6-8, 118 
the main focus of clinically applied MCs research still is on undesired, excessive 119 
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MCs activities and their disease-promoting consequences, e.g. in atopic 120 
eczema, chronic urticaria, allergic asthma and allergic rhinitis. Yet, the 121 
physiological controls of MCs that prevent an excessive accumulation and 122 
activation of MCs in normal human tissues in situ have been much less studied 123 
and are therefore only very incompletely understood. Thus, it remains a major 124 
unmet challenge for translational MCs research to identify important 125 
endogenous controls that prevent excessive MCs activation and numbers within 126 
healthy human tissues (as opposed to cell culture conditions, where MC 127 
behaviour is generally studied in the – highly artificial - absence of complex 128 
regulatory cues that normally emanate from their local tissue environment). 129 
Therefore, these endogenous controls are best studied under in situ-conditions. 130 
In the human system, they can best be characterized in human skin, since the 131 
latter is easily accessible, very rich in MCs9 and becomes frequently available 132 
during elective plastic surgery. It is important to remember that immature bone 133 
marrow-derived MC progenitors not only are deposited in peripheral tissues, 134 
such as skin, where they complete their development1, 2. Mature skin MCs can 135 
also be generated in situ from resident progenitor cells in the absence of bone 136 
marrow, namely in the stroma of organ-cultured murine and human hair follicles 137 
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(HFs), the follicular connective tissue sheath (CTS)10, 11. Therefore, we 138 
hypothesized that robust mechanisms must be in place to avoid excessive 139 
increases in MCs numbers by limiting the intracutaneous maturation of MCs 140 
from resident progenitor cells within human skin, namely from resident, CTS-141 
associated MC progenitors10,11. 142 
Given the pivotal dependence of MCs on signals from their local tissue milieu1, 5, 143 
8, it is critical to elucidate the behaviour of normal primary human MCs within 144 
their natural tissue environment. In this context, neuroendocrine controls of MCs 145 
are of particular interest since neuromediators regulate multiple human skin 146 
MCs functions, e.g. during innate immune defense, neurogenic inflammation, 147 
angiogenesis, wound healing and hair growth8, 10, 12. Moreover, the maturation 148 
of human CTS-MCs from resident precursors and/or their activation are strongly 149 
stimulated by prototypic stress-associated mediators, namely by corticotropin-150 
releasing hormone11, 13 and substance P14. Thus, the organ culture of healthy, 151 
adult human scalp HFs with their MCs-rich CTS11, 14 provides an unconventional, 152 
but highly instructive, accessible, physiologically and clinically relevant human 153 
model system for studying primary skin MCs, intracutaneous MC progenitors, 154 
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and their neuroendocrine controls within a precisely defined mesenchymal 155 
compartment in situ. 156 
Besides their multiple functions in the nervous system, endocannabinoids are 157 
now recognized as important neuroendocrine regulators of MC biology15-18. The 158 
endocannabinoid system (ECS) consists of cannabinoid receptors (CBs), their 159 
endogenous ligands (i.e. endocannabinoids, such as anandamide [AEA] and 2-160 
arachidonoylglycerol [2-AG]), and enzymes responsible for endocannabinoid 161 
synthesis and degradation15, 19-22. However, the role of the ECS in the regulation 162 
of primary human MCs in general, and of human skin MCs in situ in particular, 163 
remains unknown. Moreover, there are several conflicting reports on how CB 164 
stimulation impacts on rodent or human MC lines in vitro (for details, see 165 
Supplementary Introduction in the Online). Furthermore, it remains to be studied 166 
whether the ECS affects MC maturation from human progenitor cells in situ.  167 
 168 
Therefore, we have investigated whether and how CB stimulation/inhibition 169 
affects normal, experimentally unmanipulated human skin MCs in situ23. 170 
Specifically, we asked whether resident MCs in the CTS of HFs express 171 
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functional CB1 and whether the local ECS regulates their activation and/or 172 
maturation from resident progenitor cells.173 
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METHODS 174 
HF Organ Culture 175 
Human scalp HFs in the anagen VI stage of the hair cycle24, 25 were 176 
microdissected and organ-cultured as described previously11, 14, 23. Human 177 
tissue collection and handling was performed according to Helsinki guidelines, 178 
after Institutional Research Ethics approval (University of Lübeck) and informed 179 
patient consent. In total, 414 anagen VI HFs were isolated from excess normal 180 
occipital and temporal scalp skin obtained from eight healthy patients (aged 49-181 
72, average: 59) undergoing routine face-lift surgery. HF organ culture details 182 
are given in the supplementary Online Methods. 183 
 184 
Mast cell histochemistry  185 
Mature human skin MCs were detected with two sensitive histochemical 186 
staining methods: toluidine blue and Leder’s esterase histochemistry11. 187 
 188 
Quantitative immunohistochemistry 189 
Kit, CB1, tryptase, chymase and FcRI antigens were immunodetected in situ 190 
using the highly sensitive tyramide signal amplification (TSA) technique (Perkin 191 
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Elmer, Boston, MA) according to the manufacturer’s protocol, and were 192 
assessed by quantitative immunohistomorphometry with the help of Image J 193 
(National Institutes of Health, Bethesda, MD) in precisely defined reference 194 
areas (details: see supplementary Online Methods).  195 
 196 
CB1 knock-down in situ 197 
All reagents required for transfection (human CB1 siRNA (sc-39910), control 198 
(scrambled, SCR) siRNA (sc-37007), siRNA transfection reagent (sc-29528) 199 
and siRNA transfection Medium (sc-36868)) were obtained from Santa Cruz 200 
Biotechnology Inc (Santa Cruz, CA). HF transfection was performed according 201 
to the manufacturer’s protocol (details: see supplementary Methods in the 202 
Online).  203 
 204 
Statistical Analysis 205 
Data were analyzed using either the Mann-Whitney U-test or Student’s t-test for 206 
unpaired samples, using Prism 4.0 software (GraphPad Prism Program, 207 
GraphPad, San Diego, CA). p values <0.05 were regarded as significant. All 208 
data in the Figure are expressed as mean + SEM. * P<0.05, ** P<0.01, *** 209 
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P<0.001 for the indicated comparisons.210 
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RESULTS 211 
 212 
Human CTS-MCs express CB1 213 
Human scalp HFs, including their MCs-rich connective tissue sheath (CTS), 214 
express CB1 mRNA and protein, but not CB220. Therefore, we first asked 215 
whether cells positive for Kit (CD117, a marker that identifies even relatively 216 
immature MCs5, 11, 26) within the CTS11, 14 (which does not contain any Kit+ 217 
melanocytes), express CB1. By immunohistology, 75.5% of Kit+ CTS-MCs 218 
prominently co-expressed CB1, both in organ-cultured HFs (Figures 1A and B) 219 
and in intact human scalp skin (Figure 1C). The highly CB1-selective 220 
fluorescent ligand, Tocrifluor T1117, bound directly to Kit+ CTS-MCs (Figure 1D), 221 
demonstrating that these CB1 receptors display functional and specific binding 222 
activity. 223 
 224 
CB1 inhibition induces CTS-MCs activation and increases their number 225 
We then assessed whether treatment with the prototypic endocannabinoid, AEA 226 
(30 M)15, 21, 23, or with the selective CB1 agonist, ACEA (30 M)27 altered the 227 
total number of histochemically detectable CTS-MCs and/or their activation 228 
16 
 
status (degranulation). Interestingly, this was not the case (Figures 2B-E and 229 
Figures S1A and B in the Online). 230 
 231 
In contrast, the selective CB1 antagonist, AM251 (1 M)15, 23, significantly 232 
increased both the number of mature CTS-MCs and their degranulation 233 
(Figures 2B-E, Figures S1A and B in the Online). These effects were completely 234 
abrogated by co-incubation with AEA or ACEA (Figures 2B-E, Figures S1A and 235 
B in the Online). High resolution light microscopy independently confirmed that 236 
selectively antagonizing CB1 significantly up-regulated CTS-MCs degranulation 237 
(Figures S1D and E in the Online). By transmission electron microscopy, 238 
AM251-treated MCs showed the typical ultrastructural morphology of 239 
degranulated human MCsS27 (Figure S1F in the Online).  240 
 241 
Thus, antagonizing CB1-mediated signaling clearly increases human skin MC 242 
degranulation in situ. This conflicts with a previous report that the CB1 243 
antagonist, AM281, does not affect the degranulation of RBL-2H3 cells by 244 
itself28.  245 
 246 
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CB1 inhibition induces CTS-MCs maturation, but not proliferation 247 
Next, we studied the impact of CB1 stimulation/inhibition on the number of Kit+ 248 
cells. In human skin mesenchyme, Kit is expressed almost exclusively by MCs, 249 
and Kit immunohistology allows visualization of both, more immature MCs and 250 
mature MC populations than is possible with classical MC histochemistry, which 251 
depends on the demonstration of metachromatic granules1, 11, 14. Surprisingly, 252 
CB1 inhibition up-regulated the number of Kit+ human CTS-MCs in situ (Figures 253 
3A-C) (since we cannot exclude that CB1-negative, but Kit+ CTS-MCs were 254 
also counted, particularly in the control group, the real effect of CB1 blockade 255 
on CTS-MCs may well be even more significant than is apparent from Figure 3B 256 
and C). Interestingly, however, AM251 altered neither the number of Ki67+/Kit+ 257 
cells (Figure 3D) nor TUNEL+/Kit+ cells (Figure 3F). Most Kit+ CTS cells were 258 
Ki67-negative in both control and AM251 treated organ-cultured HF (Figure 3E). 259 
This suggests that the increased number of Kit+ CTS-MCs seen after CB1 260 
inhibition does not primarily result from stimulating the proliferation or inhibiting 261 
the apoptosis of resident MCs. Although no statistically significant differences in 262 
the number of Ki67+/Kit+ cells were seen between test and control groups, it 263 
cannot be excluded that availability of a larger -“n”- of human HFs for study 264 
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might have revealed a slight, significant difference. However, it is unlikely that 265 
this would explain the large differences seen in the total number of 266 
histochemcially and immunohistologically detectable MCs during such a short 267 
HF organ culture period (24 hrs). 268 
 269 
To independently validate this concept, we assessed the expression of antigens 270 
characteristically found on/in mature MCs, i.e. the MC proteases tryptase and 271 
chymase, and the high-affinity receptor for IgE, FcRI1, 5, 26, 29. Indeed, multiple 272 
cells positive for tryptase, FcRI, or chymase were detected in the CTS of 273 
organ-cultured HFs, and their number was significantly increased by AM251 274 
treatment (Figures 3G-I).  275 
 276 
This suggests that CB1 blockade, rather than affecting the 277 
proliferation/apoptosis3 of resident mature CTS-MCs, first, stimulates the 278 
differentiation of resident, highly immature, Kit-negative MC progenitors into Kit+ 279 
MCs, and subsequently promotes their differentiation into fully mature 280 
tryptase+/chymase+/ FcRI+ MCs (note that in our organ-culture assay, MC 281 
precursors could not possibly have been recruited from the circulation or bone 282 
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marrow, even though these resident MC progenitors may well have immigrated 283 
from the bone marrow into the HF-CTS in utero and/or postnatal life). Thus, 284 
constitutive CB1 stimulation is required to avoid the excessive intracutaneous 285 
maturation of functional MCs from resident progenitor cells within healthy 286 
human skin. 287 
 288 
CB1 gene knockdown is possible in organ-cultured human HFs 289 
To further probe this novel and provocative concept by experimentally reducing 290 
the possibility of endocannabinoids to signal via CB1, CB1 gene silencing was 291 
attempted by standard siRNA technology. Successful knock-down was 292 
demonstrated by a significant down-regulation of CB1 immunoreactivity 293 
(Figures 4A, B and Figure S2A in the Online) as well as by QPCR (which 294 
demonstrated a reduction in the intrafollicular CB1 transcript level; data not 295 
shown). Additional functional evidence that CB1 knockdown was successful 296 
arose from the MC effects reported below.  297 
 298 
Continuous CB1 stimulation by endocannabinoids controls the number 299 
and activation of human CTS-MCs in situ 300 
20 
 
CB1 knockdown significantly increased the number of CTS-MCs that were 301 
detectable by either histochemistry or immunohistology (Kit+, tryptase+), and 302 
increased their degranulation: The CTS of CB1 siRNA-treated human HFs 303 
contained greater numbers of mature, degranulated MCs than the CTS of HFs 304 
treated with scrambled oligos) (Figures 5A-E, H and I). Interestingly, Kit 305 
immunoreactivity also significantly increased in the CTS of CB1-knock-down 306 
HFs (Figure 5F). CB1 knockdown decreased intracellular (Figure S3B, Online), 307 
but increased intercellular tryptase immunoreactivity (Figures S3A and C, 308 
Online). This suggests that tryptase was actively secreted after CB1 knockdown. 309 
However, CB1 knockdown did not significantly elevate tryptase levels in the 310 
culture medium (Figure S3D, Online), possibly due to the well-recognized 311 
strong binding of secreted tryptase to collagenS28. In fact, many extracellularly 312 
located, tryptase+ granules were detectable in the collagen-rich CTS, most 313 
prominently in CB1 siRNA treated HFs (Figure S3A in the Online). CB1 gene 314 
knockdown did not stimulate CTS-MC proliferation in situ (Figure 5G). 315 
 316 
Taken together, this suggests that, under physiological conditions, continuous 317 
CB1 stimulation by endocannabinoids, which are present in substantial 318 
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quantities within the CTS of normal human scalp HFs23, maintains Kit 319 
expression and MC numbers/activation at a relatively low baseline level. These 320 
CB1 silencing data further support the concept that CB1 blockade stimulates 321 
the maturation of very immature, resident MC precursors in situ that are not 322 
even Kit+ yet. These then differentiate, first, into Kit+, and subsequently into 323 
tryptase+/chymase+/ FcRI+ mature MCs. 324 
 325 
Endocannabinoids inhibit excessive MCs activation via CB1 326 
Since excessive MCs degranulation and numbers in human skin play a key role 327 
in the pathogenesis and clinical phenotype of several major skin diseases1, 2, 6, 8, 328 
we asked whether CB1 stimulation counteracts the MCs-activating effects of 329 
classical MCs secretagogues. Quantitative MCs histomorphometry in situ 330 
demonstrated that this is the case: Both, the potent, non-selectively CB1-331 
stimulating endocannabinoid AEA (30 M)20, 23 and the CB1-specific agonist, the 332 
synthetic cannabinoid ACEA (30 M)20, 27, inhibited the degranulation-promoting 333 
effects of key endogenous and exogenous MCs activators: substance P (10-10 334 
M), a key mediator of stress-induced, neurogenic skin inflammation30 (Figure 335 
6A), and the standard secretagogue, compound 48/8031 (10 g/ml) (Figure 6B). 336 
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Thus, CB1 stimulation effectively counteracts excessive MC activation in normal 337 
human skin in situ. This suggests that, rather than acting on resting MCs (see 338 
Figure 2B-E and Figure S1A and B Online), the ECS of human skin may 339 
primarily tone-down activated MCs in situ.  340 
 341 
CB1 stimulation regulates human CTS-MCs maturation by controlling 342 
stem cell factor expression by the HF epithelium 343 
Human HF epithelium expresses functional CB123 and is a major source of stem 344 
cell factor (SCF)11, the key growth factor that drives MC maturation2, 5. 345 
Therefore, we asked whether CB1 stimulation/inhibition may induce the 346 
observed effects on MCs maturation and activation also indirectly, i.e. through 347 
stimulating the intrafollicular expression of SCF by CB1+ HF epithelial cells in 348 
situ.  349 
 350 
Indeed, AM251 (1 M) significantly up-regulated SCF expression in organ-351 
cultured HFs, both at the gene (Figure 7C) and protein level (Figures 7A and B). 352 
This was abrogated by co-administering ACEA (30 M) (Figures 7B and C). 353 
Furthermore, AM251 significantly increased SCF secretion into the culture 354 
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medium of ORS keratinocytes in vitro (Figure 7D). After AM251 treatment, 355 
compared to the control, SCF immunoreactivity was prominently detectable in 356 
close proximity to the cell membrane (Figure 7E). 60% of the cells treated with 357 
AM251 showed this fluorescence staining pattern, while this was observed only 358 
in 36.8 % of the cells in vehicle control group. This further suggests increased 359 
SCF secretion after blockade of CB1-mediated signaling and adds additional 360 
credence to the concept that SCF production by human HF epithelium is 361 
controlled by the ECS via CB1 stimulation. 362 
 363 
To further assess this indirect effect of CB1 inhibition by AM251 on CTS-MCs 364 
via SCF secretion by the HF epithelium10, 11, we performed additional HF organ-365 
culture for 1 day with 1 M of AM251 in the presence of 1 g/ml of SCF-366 
neutralizing antibody. When test and control groups were compared with 367 
respect to the number of Kit+ CTS-MCs, the increase in the number of Kit+ MCs 368 
after pharmacological CB1 blockade was partially, yet significantly reduced by 369 
neutralizing SCF (Figure 7F).  370 
 371 
CB1 deletion induces CTS-MCs maturation and activation in vitro 372 
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Finally, by examining CB1 knockout mice32, 33, we probed whether the novel 373 
concepts revealed above in an organ-cultured human skin appendage in situ, 374 
also apply in vivo. As expected, c-kit+ CTS-MCs were CB1-negative in these 375 
knockout mice (Figure S5, Online). Moreover, in line with our human HF organ 376 
culture data, the total number of MCs and c-kit+ cells was significantly 377 
increased in the subcutaneous CTS in the skin of CB1 knockout mice in vivo 378 
(Figures 8A, C and D). Here, the number of degranulated MCs was also 379 
significantly higher than in age- and hair cycle-matched wild type mice (Figure 380 
8B). There was no significant change in the number of Ki67/Kit double-positive 381 
CTS-MCs between CB1 knockout and WT mice (Figure 8E). This suggests that 382 
even in vivo, CB1 acts primarily on murine skin MC maturation and activation, 383 
and not at the level of MC proliferation. Taken together, these complementary 384 
murine data suggest that constitutive CB1 stimulation also is required in vivo to 385 
avoid excessive maturation and activation of skin MCs.386 
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DISCUSSION 387 
 388 
Collectively, our findings provide the first unequivocal evidence that, within their 389 
natural tissue habitat, normal human skin MCs utilize CB1-mediated signaling to 390 
limit not only their own activation/degranulation, but also their maturation from 391 
resident progenitor cells in situ. We show that CB1 stimulation/blockade has 392 
both, direct and indirect (i.e. SCF-mediated) effects on normal human skin in 393 
situ.  394 
 395 
Previous in vitro-studies, which had investigated rodent and human MC lines16, 396 
17, 28, 34-37, had painted a contradictory picture on the role of the ECS in MC 397 
activation (see Supplementary Introduction [Online] for details). Likely, this is 398 
explained by the fact that MC lines of debatable physiological/clinical relevance 399 
were studied or that isolated primary MCs were investigated in the absence of 400 
crucial physiological cues from their mesenchymal and epithelial 401 
microenvironment. Here, we document that, under maximally “physiological” in 402 
vitro- conditions, continuous “tonic” stimulation of CB1 expressed on human 403 
skin MCs by locally produced endocannabinoids maintains the number and 404 
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activities of mature MCs at a relatively low baseline level.  405 
 406 
The indirect, SCF-mediated effects of CB1 signaling revealed here provide the 407 
first indication that “tonic” CB1 signaling also appears required to avoid 408 
excessive SCF secretion in human skin. Since it is very well possible that the 409 
SCF neutralizing antibody we have used here did not completely block all SCF 410 
activity (thus explaining why the effect is not completely abrogated), our assay 411 
system does not allow one to state with certainty whether all of the effects of 412 
CB1 antagonist on MCs are “direct” or “indirect” through SCF. However, our 413 
results with Tocrifluor (Figure 1D) as well as CB1/Kit-double 414 
immunofluorescence (Figure 1A-C) make it reasonable to assume that direct, 415 
CB1-mediated effects on MCs operate side-by-side with indirect ones (i.e., CB1-416 
regulated secretion of SCF by human HF keratinocytes). 417 
 418 
Our study demonstrates that the CTS provides an important peripheral tissue 419 
site of and source for immature MC precursors, not only in mouse vibrissae 420 
HFs10, but also in healthy human skin11. Moreover, we provide the first evidence 421 
that the differentiation of these resident precursors into mature, functional MCs 422 
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is constitutively inhibited by the ECS. In contrast to rapidly proliferating hair 423 
matrix keratinocytes23 or various neuronal cell populations38, CB1-mediated 424 
signaling primarily seems to affect CTS-MC maturation and activation, but not 425 
proliferation or cell death. That this also applies to murine skin in vivo attests to 426 
the physiological relevance of human HF organ culture. 427 
 428 
While the CB1 KO mouse data confirm our human HF organ culture 429 
observations with respect to the regulation of skin MCs by CB1, it must be kept 430 
in mind that, under in vivo conditions, the MC phenomena observed in the skin 431 
of CB1 KO mice may reflect more complex mechanisms. 432 
 433 
We are currently testing how CB1 stimulation/blockade affects human mucosal 434 
type MCs in organ-cultured human nasal polyp samples, an excellent surrogate 435 
tissue for human bronchial mucosaS29. Our available pilot observations indicate 436 
that CB1 also suppresses the maturation of functional mucosa-type MCs from 437 
resident progenitor cells: Kit+ cells in human nasal polyps express CB1 in situ, 438 
and AM251 increases the total number of tryptase+ and Kit+ MCs without 439 
modulating their proliferation. (Sugawara, Hundt, Zákány, and Paus; manuscript 440 
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in preparation). This encourages one to explore whether CB1-mediated “tonic” 441 
inhibition of MC maturation and activation by the ECS is a general principle that 442 
also operates in other human MC populations than the ones investigated here 443 
in human skin. 444 
 445 
Our study strongly suggests that targeting the ECS for the down-modulation of 446 
excessive MC activities in human skin could become an attractive new 447 
therapeutic strategy in clinical medicine. Moreover, the current study 448 
encourages one to systematically dissect whether allergic diseases and many 449 
other disorders characterized by excessive MCs numbers and/or activation (e.g. 450 
in bronchial asthma, allergic rhinitis, atopic eczema, prurigo dermatoses, 451 
psoriasis, mastocytosis, and chronic urticaria) are associated with defined 452 
defects in the ECS, such as insufficient endocannabinoid synthesis, excessive 453 
endocannabinoid metabolism, and/or defective CB1-mediated signaling.  454 
 455 
Furthermore, our data call attention to the HF’s CTS as a previously ignored 456 
tissue compartment that may play an important role in excessive MC activities 457 
within inflamed, hair-bearing human skin. (We are currently examining whether 458 
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similar principles apply to MCs in the stroma of other human skin appendages 459 
such as sweat and sebaceous glands). Methodologically, we show that HF 460 
organ-culture provides an excellent, clinically relevant new in situ-model for 461 
preclinical MCs research in the human system, whose clinical relevance 462 
exceeds the traditional analysis of isolated human MCs, MC leukemia lines, or 463 
mouse models. 464 
 465 
Studying primary human MC biology and pathology under clinically relevant in 466 
situ conditions in human HF organ culture, thus, deserves to be fully discovered 467 
by mainstream MC research as a research tool that ideally complements and 468 
validates concepts derived from the study of MC lines and murine in vivo-469 
models. Available human skin organ-culture assaysS8, S30 can complement such 470 
HF organ culture systems so as to further probe whether selective CB1 agonists 471 
can be employed as an adjuvant strategy for the management of allergic and 472 
chronic inflammatory skin disorders with excessive MCs accumulation and 473 
degranulation. Even though such organ culture approaches exclude neural and 474 
perfusion-dependent inputs into skin MC biology, these two companion assay 475 
systems allow one to dissect the clinically important, but under-explored 476 
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neuroendocrine controls of skin MCs11, 14, 15, 39, 40 under conditions where critical 477 
cell-cell (e.g. MCs-fibroblast and MCs-keratinocyte) as well as cell-matrix 478 
interactions are fully preserved.  479 
 480 
Since CB1 receptors, in vitro, may signal in the absence of ligandS31, in theory, 481 
CB1 receptors might exert “tonic“ MC inhibition in human skin even in the 482 
absence of endocannabinoids. Also, it deserves to be investigated whether 483 
some patients with excessive skin MCs numbers and/or massive degranulation 484 
of skin MCs (e.g. in atopic dermatitis or chronic urticaria) display CB1 receptor 485 
mutations or CB1 receptor polymorphisms that incapacitate this “tonic” inhibitory 486 
signaling system. Similar effects could be brought about in genetically 487 
susceptible individuals by insufficient intracutaneous endocannabinoid 488 
synthesis and/or excessive endocannabinoid degradationS32. 489 
 490 
Although Paul Ehrlich himself, the discoverer of MCs, had already noted that 491 
skin MCs are found in highest density around blood vessels, nerves and HFs, 492 
their physiological functions in these specific locations remain to be fully 493 
explored. In selected peripheral tissue sites, such as HFs, MCs have been 494 
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proposed to bestow “some low-level immune privilege”7 (note that HFs are 495 
immunoprivileged mini-organsS33). Such an immunoinhibitory role of 496 
perifollicular MCs would make it particularly important that excessive, pro-497 
inflammatory MCs activation and excessive numbers of mature MCs are strictly 498 
avoided in human skin. The constitutive, inhibitory “endocannabinoid tone” 499 
revealed here may represent one such mechanism. Moreover, therapeutic 500 
stimulation of this inhibitory pathway offers an attractive alternative to, and 501 
complementation of, promoting MC apoptosis3 where this is clinically desired.502 
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Figure legends 633 
 634 
Figure 1. CB1 expression on CTS-MCs 635 
A. Kit and CB1 double+ CTS cells within organ-cultured human HFs and 636 
isolated scalp skin (C). B. A high magnification image shown in A by laser 637 
scanning confocal microscopy. D. Kit immunostaining with 1-day organ-cultured 638 
human HFs with Tocrifluor (1 M). Arrow denotes double+ cell. ORS=outer root 639 
sheath. NC=negative control. 640 
 641 
Figure 2. Effect of CB1 signaling on CTS-MC number and degranulation 642 
status 643 
A. “Degranulated” (Arrow head) and “non-degranulated” (Arrow) CTS-MCs were 644 
detected by Leder’s esterase histochemistry. The number of degranulated (B 645 
and C) and total CTS-MCs (D and E) per visual field in 1 day-cultured HFs with 646 
AEA (30 M), ACEA (30 M) and AM251 was analyzed.  647 
 648 
Figure 3. CTS-MCs differentiation and proliferation 649 
A. Kit immunohistology with organ-cultured HFs. B. and C. Quantitative 650 
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immunohistomorphometry of Kit+ cells in organ-cultured HFs. D. Quantitative 651 
immunohistomorphometry of Kit/Ki67 double+ cells. E. Yellow-arrow denotes 652 
Ki67+ proliferative hair matrix keratinocytes. Green-arrow denotes Kit+/Ki67- 653 
cells. F. Quantitative immunohistomorphometry of Kit/TUNEL double+ cells. 654 
Quantitative immunohistomorphometry of FcRI (G), tryptase (H), and 655 
chymase (I)+ cells. 656 
 657 
Figure 4. CB1 gene knockdown is possible in human HFs 658 
A. (Upper panel) Representative images of CB1 immunohistochemistry with 659 
TFE, SCR, and CB1 siRNA treated HFs. (lower panel) High magnification 660 
images of CB1+ ORS keratinocytes of each treatment group. Arrows denote 661 
positive immunoreactivity. B. Quantitative immunohistomorphometry of CB1 662 
immunohistochemistry with CB1 siRNA treated human HFs. 663 
 664 
Figure 5. CB1 knockdown increases degranulated and total CTS-MCs in 665 
situ.  666 
A. Leder’s-esterase histochemistry. B. Quantitative histomorphometry of 667 
degranulated CTS-MCs. C. Quantitative histomorphometry of total CTS-MCs. D. 668 
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Kit immunohistology. E. Quantitative immunohistomorphometry of Kit+ cells. F. 669 
Quantitative analysis of Kit immunoreactivity in Kit+ cells. G. Quantitative 670 
immunohistomorphometry of Kit/Ki67 double+ cells. H. Tryptase 671 
immunohistology. I. Quantitative immunohistomorphometry of tryptase+ cells. 672 
 673 
Figure 6. Inhibitory effects of cannabinoids on human skin MCs 674 
degranulation induced by endogenous or exogenous MC secretagogues. 675 
Quantitative histomorphometry of CTS-MCs degranulation detected by leder’s-676 
esterase histochemistry in substance P (10-10M) (A) and compound 48/80 (10 677 
g/ml) (B) treated organ-cultured human HFs.  678 
 679 
Figure 7. Dependence of CB1-mediated CTS-MC effects on SCF 680 
A. SCF immunohistology. B. Quantitative analysis of SCF immunoreactivity. C. 681 
QPCR analysis for SCF with 1-day organ-cultured HFs. D. SCF measurement 682 
in ORS keratinocytes culture medium. E. SCF immunocytochemistry. F. 683 
Quantitative immunohistomorphometry of Kit+ cells in organ-cultured HFs with 684 
AM251 (1 M) or/and SCF neutralizing antibody (1 g/ml). ORS=outer root 685 
sheath. 686 
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 687 
Figure 8. In vivo effects of CB1 knock-out on CTS-MC number, 688 
degranulation and proliferation in mice  689 
A. Leder’s-esterase histochemistry. Arrows denote CTS-MCs. B. Quantitative 690 
histomorphometry of the number of degranulated CTS-MCs. C. Quantitative 691 
histomorphometry of the number of total CTS-MCs. D. Quantitative 692 
immunohistomorphometry of the number of c-kit+ cells. E. Quantitative 693 
immunohistomorphometry of the number of c-kit/Ki67 double+ cells. 694 
 695 
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Supplementary Introduction 716 
 717 
There are conflicting reports on how CB stimulation impacts on rodent or human 718 
MC lines in vitro. For example, the CB1 and 2 agonist, CP55940, and the CB1 719 
agonist, methanandamide, reportedly inhibited IgE-mediated MC degranulation 720 
in the RBL-2H3 MC line in vitro. These effects were reversed by treatment with 721 
the CB1 antagonist, AM281; however, administration of this CB1 antagonist 722 
alone did not affect MC degranulation1. Methanandamide reportedly also 723 
inhibited IgE-mediated MC degranulation in primary murine bone marrow-724 
derived MCs in vitro2. In RBL-2H3 cells, endocannabinoid, 725 
palmitoylethanolamide, produced a small, but significant reduction in antigen-726 
stimulated serotonin release at high concentrations, whereas anandamide was 727 
without effect. In contrast, the endocannabinoid, 2-arachidonoylglycerol (2-AG) 728 
and methanandimide both increased the antigen-stimulated MC degranulation3. 729 
Palmitoylethanolamide, but not anandamide downmodulated MC activation via 730 
CB2 in same cell line4. Furthermore, the phytocannabinoid compound, 731 
cannabidiol triggered RBL-2H3 cell degranulation5. 9-tetrahydrocannabidol and 732 
8-tetrahydrocannabidol also induced histamine release from rat peritoneal MCs 733 
in vitro, apparently in a CB1/CB2-independent manner, while endocannabinoids 734 
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and their analogues neither induced histamine secretion, nor promoted 735 
compound 48/80-indued degranulation6. Concerning human MCs, it has been 736 
reported that supernatants from SW756 cervical carcinoma cells stimulated 737 
degranulation of the human MC line, LAD2, which was inhibited by CB2 738 
stimulation7.  739 
This leaves us with a confusing and contradictory picture of the role that CB1 740 
versus CB2 stimulation may play in the control of MC activation. Moreover, it 741 
remains completely unknown how the ECS impacts on primary human MCs, 742 
and under clinically relevant conditions, e.g. on human skin MCs in situ.743 
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Supplementary Methods 744 
 745 
Methods 746 
Reagents 747 
AEA, ACEA, AM251, substance P, and compound 48/80 were purchased from 748 
Sigma-Aldrich (Taufkirchen, Germany), whereas 5-749 
carboxytetramethylrhodamine (5-TAMRA) conjugated AM251, Tocrifluor was 750 
from Tocris Bioscience (Bristol, UK). 751 
 752 
HF Organ Culture 753 
Isolated HFs were maintained in supplemented serum-free William’s E 754 
medium8-11. HFs were first incubated overnight to adapt to culture conditions 755 
after which the medium was replaced and vehicle or test substances was added. 756 
For the organ culture with MC secretagogues, substance P and compound 757 
48/80, HFs were first treated with AEA (30 M) or ACEA (30 M) for 1 day after 758 
the overnight incubation. Then the HFs were treated with either substance P 759 
(10-10 M) or compound 48/80 (10 g/ml) in the combination with AEA or ACEA 760 
for additional 1 day. Following culturing for the time indicated, HFs were then 761 
cryoembedded and prepared for histology and immunohistochemistry. 762 
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 763 
Immunohistochemistry 764 
For the detection of Kit, CB1, tryptase, chymase and FcRI, the highly 765 
sensitive tyramide signal amplification (TSA) technique (Perkin Elmer, Boston, 766 
MA) was applied. Cryosections were incubated overnight at 4°C with primary 767 
antibodies, either rabbit anti-human CD117 (Cell Marque Corp., Rocklin, CA, 768 
USA) at 1:1000, rat anti-mouse CD117 (BD Biosciences, San Jose, CA, USA) 769 
at 1:5000, rabbit anti-human CB1 (Cayman Chemical, Michigan, USA, or Santa 770 
Cruz, CA, USA) at 1:400, or mouse anti-human FcRI (Acris GmbH, 771 
Hiddenhausen, Germany) at 1:1000, or mouse anti-human chymase (Abcam 772 
plc) at 1:1000, or mouse anti-human tryptase (Abcam plc, Cambridge, UK) at 773 
1:5000 diluted in TNB (Tris, NaOH, Blocking reagent, TSA kit; Perkin-Elmer). 774 
Thereafter, the cryosections were incubated with goat biotinylated antibodies 775 
against rabbit or mouse IgG (Jackson Immunoresearch Laboratories, West 776 
Grove, PA) at 1:200 in TNB for 45 min at room temperature (RT). The TSA 777 
method was applied according to the manufacturer’s protocol.  778 
 779 
Double-immunostaining for Kit and CB1 was performed by using the TSA 780 
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technique. Briefly, cryosections were incubated overnight at 4°C with a primary 781 
antibody against Kit followed by biotinylated goat anti-rabbit IgG (Jackson 782 
Immunoresearch Laboratories) (1:200 in TNB, 45 min, RT). Sections were then 783 
incubated with streptavidin-conjugated horseradish peroxidase (1:100, 30 min, 784 
TSA kit) and were finally incubated with fluorescein isothiocyanate (FITC) 785 
conjugated tyramide (1:50, TSA kit). After careful washing with TNT wash buffer 786 
(0.1 M Trizma hydrochloride, 0.15 M NaCl and 0.05% Tween 20), sections were 787 
then incubated overnight with rabbit anti-human CB1 antibody (Santa Cruz) at 788 
4 °C followed by incubation with goat biotinylated antibody against rabbit IgG 789 
(Jackson Immunoresearch Laboratories) (1:200 in TNB, 45 min, RT). After 790 
incubating with streptavidine-conjugated horseradish peroxidase (1:100, 30 min, 791 
TSA kit) sections were incubated with tetramer rhodamine conjugated tyramide 792 
(1:50, TSA kit). 793 
 794 
To study the proliferation of the Kit+ cells, double-immunostaining for Ki-67 and 795 
Kit was performed. Briefly, after the staining for Kit using a TSA kit, sections 796 
were incubated overnight at 4°C with a mouse anti-human Ki67 antibody 797 
(DAKO, Hamburg, Germany) at 1:20 in phosphate-buffered saline (PBS) for 798 
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detecting human Ki67, or with rat anti-mouse Ki67 antibody (DAKO) at 1:100 in 799 
PBS for detecting mouse Ki67+ cells. Sections were then washed with PBS, 800 
followed by incubation with rhodamine conjugated goat anti-mouse IgG or goat 801 
anti-rat IgG (Jackson Immunoresearch Laboratories) (1:200 in PBS, 45 min) at 802 
RT.  803 
 804 
To evaluate the apoptosis of Kit+ cells, Kit immunostaining and terminal dUTP 805 
nick-end labeling (TUNEL) was performed on the same sections. Briefly, after 806 
the immunostaining for Kit, sections were incubated with a digoxigenin-deoxy-807 
UTP (ApopTag fluorescein in situ apoptosis detection kit; Millipore Corp., 808 
Billerica, MA) in the presence of terminal deoxynucleotidyl transferase (60 min) 809 
at 37°C. After the incubation with Stop/Wash buffer (ApopTag kit) (10 min, RT) 810 
and the additional wash with PBS, TUNEL-positive cells were visualized by an 811 
antidigoxigenin fluorescein isothiocyanate-conjugated antibody (ApopTag kit) 812 
(30 min, at RT). 813 
 814 
To evaluate the immunoreactivity of CB1 in CB1 siRNA-treated HFs as well as 815 
in intact human scalp skin sections, the expression of CB1 in the HFs was 816 
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visualized using the peroxidase-based avidin-biotin complex method (Vectastain 817 
Elite ABC kit; Vector Laboratories, Burlingame, CA). Frozen sections were fixed 818 
in cold acetone and rinsed with PBS, and endogenous peroxidase activity was 819 
saturated with 0.3 % H2O2 in PBS for 15 min. After the incubation with 5 % of 820 
normal goat serum, sections were incubated with rabbit anti-human CB1 821 
antibody (Cayman chemical) (1:40 in PBS) at 4°C overnight. After incubation 822 
with a biotinylated goat anti-rabbit antibody (Jackson Immunoresearch 823 
Laboratories) (45 min, at RT), sections were treated with Vectastain ABC 824 
reagent (Vector laboratories) and visualized with AEC (3-amino-9ethylcarbazol) 825 
(Vector laboratories). As negative controls, the appropriate primary antibodies 826 
were omitted from the procedure. The specificity of CB1 immunostaining was 827 
measured on intact human scalp skin sections (Figure S2B in the Online) 828 
mouse brain sections (positive control) which clearly demonstrated positive CB1 829 
immunoreactivity in the expected areas (data not shown). 830 
For detecting SCF in organ cultured human HFs as well as isolated human 831 
ORS keratinocytes, indirect immunofluorescence method was applied using 832 
anti-human SCF (Acris GmbH) at 1:20 in PBS as a primary antibody and FITC 833 
(Rhodamine for ORS keratinocytes) conjugated goat anti-mouse IgG at 1:200 in 834 
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PBS as a secondary antibody. Intact human scalp skin sample was used as a 835 
positive control (supplementary Figure S4). 836 
 837 
The immunoreactivity of CB1, Kit, tryptase and SCF in defined reference areas 838 
was assessed by quantitative immunohistomorphometry9, 11-13 using the ImageJ 839 
software (National Institutes of Health, Bethesda, MD). 840 
 841 
For counting MCs, MCs were classified as “degranulated” when five or more 842 
extracellularly located metachromatic granules could be detected 843 
histochemically at high magnification (x400) by light microscopy (visual field). 844 
The number of degranulated and total CTS-MCs around the HF per visual field 845 
was counted, and at least 13 visual fields per HF in total were evaluated. 846 
Some degranulated MCs were detected even in the vehicle control group 847 
(Figures S1A and B in the Online). This is in line with previously reported data9. 848 
The percentage of degranulated MCs in freshly microdissected HFs evaluated 849 
by leder’s-esterase histochemistry was significantly higher than in 850 
unmanipulated human skin, suggesting that the trauma of HF microdissection 851 
caused some degree of MCs degranulation. MCs in freshly isolated skin also 852 
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displayed a steady-state level of degranulation (Figure S1C in the Online). 853 
 854 
High magnification images of Kit and CB1 double+ cell were taken by laser 855 
scanning confocal microscopy (Fluoview 300, Olympus Tokyo, Japan) running 856 
Fluoview 2.1 software (Olympus). 857 
 858 
High resolution light microscopy (HRLM) and Transmission electron 859 
microscopy (TEM) 860 
Organ cultured human scalp HFs were immersed in a mixture containing 2% 861 
paraformaldehyde, 2.5% glutaraldehyde, and 0.025% CaCl2 in 0.1 mol/L 862 
sodium cacodylate buffer, pH 7.4 and fixed. The specimens were then 863 
immersed in 1% osmium tetroxide in the same buffer. The samples were 864 
dehydrated in a gradient series of ethanol, immersed in propylene oxide, and 865 
embedded in plastic resin. Thin and thick sections were generated on a Leica 866 
Ultra UCT (Leica, Vienna, Austria). 1 m of thick sections were prepared for an 867 
alkaline-Giemsa histochemistry14. MCs were defined as degranulated according 868 
to the previous article14. Thin sections were stained with uranyl acetate and lead 869 
citrate and observed with an electron microscope (JEM-1200EXII, JEOL, Tokyo, 870 
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Japan). 871 
 872 
Quantitative PCR 873 
Expressions of specific mRNA transcripts of SCF were analyzed by quantitative 874 
real-time PCR performed on an ABI PRISM 7000 Sequence Detection System 875 
(Applied Biosystems, Foster City, CA, USA) as described before12, 13 using 876 
TaqMan primers and probes (Assay ID: Hs00241497_m1 for human SCF). 877 
Three different internal housekeeping genes, glyceraldehyde 3-phosphate 878 
dehydrogenase (GAPDH), -actin (ACTB), cyclophilin A (PPIA) were assessed 879 
(Assay ID: Hs99999905_m1 for GAPDH, Hs99999903_m1 for ACTB, and 880 
Hs99999904_m1 for PPIA). The amount of SCF transcripts was normalized to 881 
those of the control genes as previously reported12, 13. 882 
 883 
CB1 knock-down in situ 884 
All reagents required for transfection (human CB1 siRNA (sc-39910), control 885 
(scrambled, SCR) siRNA (sc-37007), siRNA transfection reagent (sc-29528) 886 
and siRNA transfection Medium (sc-36868)) were obtained from Santa Cruz. HF 887 
transfection was performed according to the manufacturer’s protocol. Briefly, 888 
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freshly isolated human HFs were kept in cold William’s E medium right before 889 
the transfection. During transfection CB1 specific siRNA or control siRNA (2.5 890 
l) and siRNA transfection reagent (2 l) was mixed in transfection medium 891 
(500 l) per well (24 well-plate). After the careful wash, HFs were applied to 892 
each well (3 HFs per well) and incubated at 37 °C in a CO2 incubator for 6 893 
hours after which the medium was replaced with supplemented William’s E 894 
medium. HFs were cryo-embedded 24 hrs following transfection. 895 
TFE=transfection reagent treated HFs, SCR=scrambled siRNA treated HFs, 896 
CB1 siRNA=CB1 siRNA treated HFs. 897 
 898 
CB1 knock-out mice 899 
Targeted disruption of the CB1 receptor gene was performed by replacing the 900 
CB1 coding sequence with a non-receptor sequence by homologous 901 
recombination in MPI2 embryonic stem cells. Mutant mice have been crossed to 902 
C57BL/GJ animals for more than 13 generations and are therefore considered 903 
to be congenic for this genetic background. Homozygous CB1−/− mice and 904 
wild-type (CB1+/+) animals were generated by matings of heterozygous 905 
(CB1+/−) mice15, 16. 906 
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 907 
Tryptase immunoassay 908 
Organ cultured human scalp HFs were treated with CB1 siRNA for 1 day. The 909 
culture supernatants of these HFs were collected for the analysis. The level of 910 
tryptase was measured by a fluorescent enzyme immunoassay using a 911 
commercial assay from Phadia (ImmunoCap™ Tryptase, Uppsala, Sweden). 912 
The principle of the assay is based on a monoclonal anti-tryptase capture 913 
antibody which binds specifically tryptase. After washing, β-galactosidase-914 
labeled anti-tryptase antibody is added. Bound complexes are stained by the 915 
conversion of 4-methyliumbelliferyl-β-D-galactoside. The fluorescent signal is 916 
correlated with the amount of tryptase. 917 
 918 
Isolation and culture of ORS keratinocytes 919 
Isolation and culture of human ORS keratinocytes were performed according to 920 
our established protocol17. Briefly, ORS keratinocytes were isolated by an 921 
enzymatic digestion (0.2 % trypsin, 0.1 % ethylenediaminetetraacetic acid 922 
(EDTA) in calcium and magnesium free phosphate buffered saline (CMF-PBS) 923 
for 1 hour at 37°C; all from Sigma Aldrich) and gentle trituration. Following 924 
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isolation, the single cell suspension was removed, collected by centrifugation 925 
(1000 rpm for 10 min) and resuspended in ORS keratinocyte culturing medium. 926 
It comprises 3:1 mixture of Dulbecco’s modified Eagle medium (DMEM; 927 
supplemented with L- glutamine, Na-pyruvate, 4.5 g/L glucose) and Ham’s F12 928 
(both from Invitrogen), supplemented with 10% Fetal Clone II (Hyclone) and 5 929 
µg/ml insulin, 0.4 µg/ml hydrocortisone, 2.43 µg/ml adenin, 2 nM 930 
triiodothyronine, 0.1 nM cholera toxin, 10 ng/ml EGF, 1 mM ascorbyl-2-931 
phosphate, 100 U/ml penicillin G, and 25 µg/ml gentamycin (all from Sigma). 932 
ORS keratinocytes were seeded and cultured on mitomycin treated human 933 
dermal fibroblast feeder-layer in ORS keratinocyte culturing medium. 934 
 935 
SCF immunoassay 936 
The supernates of human ORS keratinocytes culture were collected and 937 
freezed at -80 °C until the assay was performed. Samples were analyzed their 938 
SCF levels by Quantikine Human SCF ELISA Kit (R&D Systems).  939 
 940 
Mouse skin harvesting was performed under an appropriate animal 941 
experimentation license obtained by the University of Bonn. Human tissue use 942 
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was approved by the Ethics Committee, University of Lübeck. 943 
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Supplementary Discussion 944 
 945 
Our results show that CB1 blockade effects not only directly on MCs, but also 946 
induces SCF secretion by human HF keratinocytes. This suggests that, under 947 
physiological conditions, “tonic” CB1 stimulation by the intracutaneous ECS 948 
keeps SCF production by human HF epithelium at a relatively low level and that 949 
blocking CB1 releases this endogenous “molecular brake” on SCF production. 950 
Increased SCF secretion then serves as a stimulus for the intracutaneous 951 
maturation of MCs from resident precursors in the CTS. These data not only 952 
provide the first available evidence for a link between CB1 signaling and SCF 953 
biology, but also underscore the importance of epithelial-mesenchymal 954 
interactions in human skin MC biology. 955 
 956 
Do ECS affect itching as well as tissue remodeling after inflammation? This 957 
important question has been discussed in a number of original reports and 958 
reviews, including our own18, 19. Given the limitations of our human HF organ 959 
culture system, which is unsuitable for pruritus research, evidently, we cannot 960 
provide any corresponding experimental data with this assay on how the ECS 961 
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may affect itch (pruritogenic pruritus) and its processing in the central system 962 
after inflammation. For this, CB1 KO mice are a more appropriate model.  963 
However, a couple of relevant reports on the effects of endocannabinoids on 964 
itch already suggest that the ECS may indeed play an important role in itch. For 965 
example, topical application of the endocannabinoid, PEA (N-966 
palmitoylethanolamine), to patients with mild to moderate atopic eczema 967 
significantly reduced the intensity of erythema, pruritus, excoriation, scaling, 968 
lichenification and dryness20. Since the inhibition of anandamide (AEA)-969 
degrading enzymes (such as FAAH) increases AEA levels in mice21, 22, it is 970 
interesting to note that FAAH knockout mice or FAAH inhibitor-treated mice 971 
show significant reduction in scratching without affecting locomotor behavior23. 972 
Moreover, excessive mast cell activity is well-recognized to play a key role in 973 
many itch-associated skin diseases, including allergy and atopic dermatitis, and 974 
neurogenic skin inflammation24-27. 975 
 976 
Therefore, our current data are well in line with the concept that the ECS may 977 
also modulate MC-dependent pruritogenic pruritus via reducing MC 978 
degranulation and via avoiding excessive MC maturation from resident 979 
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intracutaneous progenitor cells. Moreover, since not only HF and epidermal 980 
melanocytes, but also rapidly proliferating hair matrix keratinocytes prominently 981 
express Kit on the gene and protein level (see Peters et al.28), it is conceivable 982 
that CB1-regulated changes in the secretion of the cognate ligand (SCF) could 983 
also impact on the growth and remodeling of selected, Kit-expressing epithelial 984 
cell populations in the HF, besides direct effects of (endo-)cannabinoid effects 985 
on CB1+ HF epithelial cells. 986 
987 
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Supplementary Figure legends 988 
 989 
Supplementary Figure S1. CB1 blockade significantly increases 990 
degranulation of CTS-MCs in situ 991 
A. Percentage of degranulated CTS-MCs in organ cultured human HFs for 1 992 
day with ACEA (30 M) or/and AM251 (1 M), and with (B) AEA (30 M) or/and 993 
AM251. C. Percentage of degranulated CTS-MCs within the HFs of intact 994 
human scalp skin or isolated human scalp HFs. D. High resolution light 995 
microscopy of alkaline-Giemsa histochemistry and statistical analysis (E). F. 996 
TEM images  997 
 998 
Supplementary Figure S2. CB1 gene knockdown decreases CB1 999 
expression in situ. 1000 
A. Representative images of specific CB1 immunofluorescence in situ. 1001 
B. Representative images of CB1 immunohistochemistry with intact human 1002 
scalp skin sample (left) and negative staining control (right). Yellow arrow; 1003 
positive CB1 immunoreactivity in the epidermis and ORS (red arrow). 1004 
 1005 
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Supplementary Figure S3. Trypase immunohistology with CB1 siRNA 1006 
treated HFs and tryptase levels in the culture medium. 1007 
A. Representative image of tryptase immunohistology AM251 treated HFs. 1008 
Yellow arrow; tryptase+ intracellular immunoreactivity. Red arrows; intercellular 1009 
tryptase+ immunoreactivity. B. Quantitative immunohistomorphometry of 1010 
intracellular tryptase immunoreactivity. C. Quantitative 1011 
immunohistomorphometry of intercellular tryptase immunoreactivity. D. 1012 
Statistical analysis of tryptase levels in the HF organ culture medium. 1013 
 1014 
Supplementary Figure S4. SCF is expressed within the epidermis of 1015 
human skin. 1016 
Indirect SCF immunofluorescence images of intact human scalp skin sample. 1017 
 1018 
Supplementary Figure S5. CB1 expression in c-kit+ MCs of CB1 knockout 1019 
mice is reduced compared to wild type mice. 1020 
Double immunohistology for c-kit and CB1 in both wild type and CB1 knockout 1021 
mice (postnatal day 32). Scale bar; 5 m. 1022 
1023 
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